Peritoneal carcinomatosis

disease
On this page

Also known as abdominal carcinomatosiscarcinomatosis of the peritoneum

Summary

Peritoneal carcinomatosis (MONDO:0700336) is a disease and 120 clinical trials. Top therapeutic interventions include paclitaxel, indocyanine green acid form, and sodium thiosulfate. A subtype of peritoneum cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 120

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameperitoneal carcinomatosis
Mondo IDMONDO:0700336
ICD-111523083931
NCITC27382
UMLSC0346990
MedGen577752
Is cancer (heuristic)no

Also known as: abdominal carcinomatosis · carcinomatosis of the peritoneum · peritoneal carcinomatosis

Disease family

This is a subtype of peritoneum cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumorneoplastic disease or syndromeneoplasmcancerperitoneum cancerperitoneal carcinomatosis

Related subtypes (5): round ligament malignant neoplasm, peritoneal carcinoma, malignant peritoneal solitary fibrous tumor, malignant peritoneal mesothelioma, malignant peritoneal germ cell tumor

Subtypes (1): pseudomyxoma peritonei

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 120.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified46
PHASE236
PHASE121
PHASE1/PHASE28
PHASE2/PHASE33
PHASE33
EARLY_PHASE12
PHASE41

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05250648PHASE4RECRUITINGClinical Trial on HIPEC With Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)
NCT02758951PHASE2/PHASE3ACTIVE_NOT_RECRUITINGPerioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases
NCT03348150PHASE3ACTIVE_NOT_RECRUITINGGastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.
NCT07001748PHASE2/PHASE3RECRUITINGTesting the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
NCT01683864PHASE2/PHASE3TERMINATEDRandomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer
NCT02840331PHASE3UNKNOWNPilot Study on Intra-abdominal Photodynamic Diagnosis in Peritoneal Carcinosis
NCT03179579PHASE3UNKNOWNEfficacy of HIPEC Combined With Systemic Chemotherapy and CRS on Peritoneal Metastases From Gastric Cancer
NCT03127774PHASE2ACTIVE_NOT_RECRUITINGSurgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
NCT03280511PHASE2RECRUITINGAdjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients
NCT04107077PHASE2RECRUITINGPhase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
NCT04762953PHASE2ACTIVE_NOT_RECRUITINGStudy of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis
NCT04779554PHASE2RECRUITINGFlat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC
NCT04840264PHASE2RECRUITINGDocetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
NCT05700656PHASE1/PHASE2RECRUITINGGalunisertib Combined With Capecitabine in Advanced CRC With PM
NCT05913674PHASE2RECRUITINGTechnical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)
NCT06504147PHASE2RECRUITINGA Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
NCT07282834PHASE2RECRUITINGHeated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)
NCT07514494PHASE2RECRUITINGIntensification Treatment of Ovarian Cancer by PIPAC
NCT07593261PHASE2NOT_YET_RECRUITINGMRI-Guided Adaptive Radiotherapy for Limited Peritoneal Metastases (MARACAS Trial).
NCT01095523PHASE2WITHDRAWNProspective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases
NCT01116791PHASE2TERMINATEDCytoreductive Surgery(CRS) Plus Hyperthermic Intraoperative Peritoneal Chemotherapy(HIPC) With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer
NCT01342653PHASE2SUSPENDEDClinical Trial at Neoadjuvant Peritoneal and Systemic Chemotherapy Plus HIPEC in Gastric Carcinomatosis
NCT01379482PHASE2COMPLETEDNeo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer
NCT01443260PHASE1/PHASE2COMPLETEDA Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis
NCT01540344PHASE2TERMINATEDCombined Anticancer Treatment of Advanced Colon Cancer
NCT01575730PHASE2COMPLETEDCytoreduction Followed by Normothermic Versus Hyperthermic Intraperitoneal Intraoperative Chemoperfusion (HIPEC): a Study in Peritoneal Carcinomatosis
NCT01833832PHASE2COMPLETEDSurgery and Heated Chemotherapy for Adrenocortical Carcinoma
NCT01834469PHASE1/PHASE2COMPLETEDImaging of Peritoneal Carcinomatosis From Ovarian Carcinoma Patients
NCT02032485PHASE2COMPLETEDNear-Infrared Imaging of Peritoneal Carcinomatosis From Colorectal Cancer
NCT02040142PHASE2COMPLETEDHIPEC for Peritoneal Carcinomatosis
NCT02151448PHASE1/PHASE2COMPLETEDαDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
NCT02320448PHASE2COMPLETEDTreating Peritoneal Carcinomatosis With PIPAC
NCT02604784PHASE1/PHASE2COMPLETEDStudy of Efficacy and Safety of Laparoscopic Intra-abdominal Chemotherapy (PIPAC) Performed in Patients With Peritoneal Carcinomatosis From Colorectal, Ovarian, Gastric Cancer and Primary Peritoneal Tumors
NCT02739698PHASE2COMPLETEDRole of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus Normothermia
NCT02759588PHASE1/PHASE2COMPLETEDGL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
NCT02891447PHASE2COMPLETEDHeated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer
NCT03150628PHASE2TERMINATEDCytoreductive Surgery and Intraperitoneal Chemotherapy for Stomach CAncer: a Feasibility Study
NCT03246321PHASE2COMPLETEDPIPAC for Peritoneal Metastases of Colorectal Cancer
NCT03618758PHASE1/PHASE2COMPLETEDIntraperitoneal Paclitaxel Plus Systemic mFOLFOX6
NCT03699332PHASE1/PHASE2UNKNOWNMulti-modality Imaging in Peritoneal Carcinomatosis of Colorectal Origin

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
PACLITAXEL48
INDOCYANINE GREEN ACID FORM44
SODIUM THIOSULFATE43
INTERFERON ALFA-2B41
PASIREOTIDE41
VELIPARIB32
OLVIMULOGENE NANIVACIREPVEC31
RINTATOLIMOD31
ST. JOHN’S WORT31
EFTILAGIMOD ALFA21
PEGSITACIANINE21
CHEMBL375320203
CHEMBL407138203
CHEMBL517514403
CHEMBL45429901